ReviewDermatology practical & conceptual2023
Vitiligo: Current Therapies and Future Treatments.
Review in Dermatology practical & conceptual, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Safety and efficacy of Simvastatin in the treatment of vitiligo: a systematic review and meta-analysis of randomized controlled trials.Archives of dermatological research · 2025Pooled it
- The Influence of Sunscreen Use on Skin Pigmentation Disorders: Melasma, Post-Inflammatory Hyperpigmentation, and Vitiligo.Current issues in molecular biology · 2026Review
- Early Proteomic Alterations in Non-segmental Vitiligo Skin Following Treatment with Topical Tacrolimus.Dermatology and therapy · 2026Article
- Tofacitinib as a Promising Therapeutic Option for Vitiligo: A Systematic Review.Clinical, cosmetic and investigational dermatology · 2026Review
- Validating the Use of ICD-10 Codes for Identifying Vitiligo.JAMA dermatology · 2025Article
- Physical Activity and Psychological Health in Vitiligo Patients: A Cross-Sectional Study on Depression, Anxiety, and Stress.Health science reports · 2025Article
- Non-Cultured Melanocyte-Keratinocyte Transplantation Combined With NB-UVB Therapy for Facial Depigmentation Induced by Skin Exfoliator: A Case Report.Clinical case reports · 2025Article
- Recent clinical and mechanistic insights into vitiligo offer new treatment options for cell-specific autoimmunity.The Journal of clinical investigation · 2025Review
- Treatment of vitiligo with topical ruxolitinib: a narrative review.Drugs in context · 2025Review
- Lipid-based nanoparticles: advancing therapeutic strategies for vitiligo management.BioImpacts : BI · 2025Review
- Comprehensive analysis of life quality of patients with vitiligo in Romania: insights from a multivariate approach.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current management of vitiligo remains challenging; however, different strategies can be proposed to patients with a good efficacy in many cases. First, it is important to identify patients in the active phase of the disease because treatment should start as soon as possible to halt its progression. For patients with a stable disease, the treatment strategy is now well-stratified and is based on a combination of phototherapy (natural or in a cabin) and topical immunomodulatory agents. Surgical treatments are useful for localized and stable vitiligo, as well as for segmental vitiligo. Depigmentation remains indicated in very extensive forms. The recent approval of topical ruxolitinib cream in both the US and Europe brings new approaches for the management of vitiligo and paves the way for the development of new topical or oral targeted drugs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.